

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

Naval Daver,¹ Jorge Cortes,¹ Kate Newberry,¹ Elias Jabbour,¹ Lingsha Zhou,¹ Xuemei Wang,² Sherry Pierce,¹ Tapan Kadia,¹ Koji Sasaki,¹ Gautam Borthakur,¹ Farhad Ravandi,¹ Naveen Pemmaraju,¹ Hagop Kantarjian,¹ and Srdan Verstovsek¹

¹Department of Leukemia and ²Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

©2015 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.126821

The online version of this article has a Supplementary Appendix.

Manuscript received on March 16, 2015. Manuscript accepted on June 16, 2015.

Correspondence: ndaver@mdanderson.org

SUPPLEMENTAL DATA

Patient Evaluation

The patient evaluation schedule included a complete physical examination (every 4 weeks for the first 3 cycles, then every 12 weeks), complete blood count and comprehensive biochemistry panel including liver function tests (every week for the first 2 cycles, then every 2 weeks for 4 cycles, then every 4 weeks thereafter), pregnancy test and counseling (pregnancy test every week for the first cycle and then every 4 weeks if regular menstrual cycles, or every 2 weeks if irregular menstrual cycles), bone marrow aspiration and biopsy with cytogenetics (prior to initiation of therapy and every 12 weeks, including staining for fibrosis) and molecular testing for JAK2^{V617F} (every 12 weeks, if present before therapy). Bone marrow fibrosis and cellularity were graded according to the European consensus guidelines(29). The pyrosequencing assay to detect the 1849G>T JAK2 mutation (JAK2^{V617F}) has been previously reported(32). Responses were assessed according to the 2006 IWG-MRT criteria(33).